Last reviewed · How we verify
Tata Memorial Centre — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
6 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Curcumin Lozenges | Curcumin Lozenges | phase 3 | Natural product/polyphenol anti-inflammatory agent | NF-κB, multiple antioxidant pathways | Oncology, Oral health, Anti-inflammatory |
Therapeutic area mix
- Oncology · 3
- Oncology, Oral health, Anti-inflammatory · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Aragon Pharmaceuticals, Inc. · 1 shared drug class
- Arvinas Androgen Receptor, Inc. · 1 shared drug class
- Astellas Pharma · 1 shared drug class
- AstraZeneca · 1 shared drug class
- City of Hope Medical Center · 1 shared drug class
- Lidds AB · 1 shared drug class
- Pfizer Inc. · 1 shared drug class
- Triple Hair Inc · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Tata Memorial Centre:
- Tata Memorial Centre pipeline updates — RSS
- Tata Memorial Centre pipeline updates — Atom
- Tata Memorial Centre pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Tata Memorial Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tata-memorial-centre. Accessed 2026-06-10.